[Introduction](index=1&type=section&id=Introduction) [Company Overview](index=1&type=section&id=Company%20Overview) TransMedics is a medical technology company transforming organ transplant therapy for patients with end-stage organ failure - TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure[1](index=1&type=chunk) [Recent Highlights & CEO Commentary](index=1&type=section&id=Recent%20Highlights) The company reported strong Q2 performance with 38% revenue growth, driven by strategic execution and platform value - CEO reported a strong quarter, marked by profitable year-over-year revenue growth of **38%**[3](index=3&type=chunk) - Performance reflects successful execution of strategy, differentiated value of OCS and NOP platforms, and unique leadership position in the transplant market[3](index=3&type=chunk) - Company is focused on achieving and surpassing the target of **10,000 US NOP transplants in 2028**, while ramping up investments for future growth[3](index=3&type=chunk) [Second Quarter 2025 Financial Performance](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results) [Key Financial Metrics](index=1&type=section&id=Key%20Financial%20Metrics) The company reported significant Q2 2025 growth with a 38% revenue increase and more than doubled net income Q2 2025 Key Financial Highlights | Metric | Q2 2025 | Q2 2024 | YoY Change | | :----- | :------ | :------ | :--------- | | Total Revenue | $157.4 million | $114.3 million | +38% | | Gross Margin | 61% | 61% | Consistent | | Operating Expenses | $60.0 million | $56.8 million | +$3.2 million | | Net Income | $34.9 million | $12.2 million | +186% | | Diluted EPS | $0.92 | $0.35 | +163% | [Revenue Analysis](index=1&type=section&id=Revenue%20Analysis) Q2 2025 revenue grew 38% to $157.4 million, driven by increased OCS and NOP service utilization Q2 2025 Revenue Breakdown | Revenue Type | Q2 2025 (in thousands) | Q2 2024 (in thousands) | YoY Change | | :----------- | :--------------------- | :--------------------- | :--------- | | Net product revenue | $96,100 | $71,732 | +33.9% | | Service revenue | $61,270 | $42,573 | +44.0% | | Total revenue | $157,370 | $114,305 | +37.7% | - The increase in revenue was primarily due to increased utilization of the Organ Care System (OCS), particularly in Liver and Heart through the National OCS Program (NOP) and related NOP service revenue, fueled by the continued expansion and utilization of the aviation fleet[4](index=4&type=chunk) [Profitability and Expenses](index=1&type=section&id=Profitability%20and%20Expenses) Gross margin remained stable at 61%, while net income significantly improved to $34.9 million Q2 2025 Profitability and Expenses | Metric (in thousands) | Q2 2025 | Q2 2024 | YoY Change | | :-------------------- | :------ | :------ | :--------- | | Gross Profit | $96,589 | $69,261 | +39.4% | | Gross Margin | 61% | 61% | Consistent | | Operating Expenses | $60,022 | $56,753 | +5.8% | | R&D and Clinical Trials | $15,934 | $13,858 | +15.0% | | SG&A | $44,088 | $42,895 | +2.8% | | Income from Operations | $36,567 | $12,508 | +192.4% | | Net Income | $34,907 | $12,194 | +186.3% | - The increase in operating expenses was driven primarily by increased research and development investment as well as investment throughout the organization to support company growth[5](index=5&type=chunk)[6](index=6&type=chunk) - Stock compensation expense in Q2 2025 was **$9.0 million**, up from **$7.3 million** in Q2 2024[6](index=6&type=chunk) [Balance Sheet Highlights](index=2&type=section&id=Balance%20Sheet%20Highlights) The company maintained a strong liquidity position with cash totaling $400.6 million as of June 30, 2025 Key Balance Sheet Items (as of June 30, 2025) | Metric (in thousands) | June 30, 2025 | Dec 31, 2024 | Change | | :----- | :------------ | :----------- | :----- | | Cash | $400,575 | $336,650 | +$63,925 | | Total Assets | $890,522 | $804,076 | +$86,446 | | Total Liabilities | $572,421 | $575,473 | -$3,052 | | Total Stockholders' Equity | $318,101 | $228,603 | +$89,498 | [2025 Financial Outlook](index=2&type=section&id=2025%20Financial%20Outlook) [2025 Financial Outlook](index=2&type=section&id=2025%20Financial%20Outlook) The company raised its full-year 2025 revenue guidance to $585-$605 million, representing 35% growth at the midpoint Full Year 2025 Revenue Guidance | Guidance Type | Range | Growth at Midpoint (YoY) | | :------------ | :---- | :----------------------- | | New FY2025 Revenue Guidance | $585 million - $605 million | 35% | | Previous FY2025 Revenue Guidance | $565 million - $585 million | N/A | [Operational Achievements and Strategic Initiatives](index=1&type=section&id=Operational%20Achievements%20and%20Strategic%20Initiatives) [Operational Achievements and Strategic Initiatives](index=1&type=section&id=Operational%20Achievements%20and%20Strategic%20Initiatives) Key Q2 achievements include FDA approval to initiate the Next-Gen OCS™ Lung trial and the launch of the NOP ACCESS™ digital ecosystem - Received conditional Investigations Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial[5](index=5&type=chunk) - Launched first-in-class OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs across the U.S[5](index=5&type=chunk) [About TransMedics Group, Inc.](index=2&type=section&id=About%20TransMedics%20Group,%20Inc.) [About TransMedics Group, Inc.](index=2&type=section&id=About%20TransMedics%20Group,%20Inc.) TransMedics is the global leader in portable warm perfusion and assessment technologies for donor organs - TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation[9](index=9&type=chunk) - The company develops technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure[9](index=9&type=chunk) [Financial Statements (Unaudited)](index=5&type=section&id=Financial%20Statements%20(Unaudited)) [Consolidated Statements of Operations](index=5&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) The statements detail financial performance for the three and six months ended June 30, 2025, showing significant growth Consolidated Statements of Operations (Three Months Ended June 30) | Metric (in thousands, except per share) | 2025 | 2024 | | :------------------------------------ | :--- | :--- | | Total revenue | $157,370 | $114,305 | | Gross profit | $96,589 | $69,261 | | Operating expenses | $60,022 | $56,753 | | Income from operations | $36,567 | $12,508 | | Net income | $34,907 | $12,194 | | Diluted Net income per share | $0.92 | $0.35 | Consolidated Statements of Operations (Six Months Ended June 30) | Metric (in thousands, except per share) | 2025 | 2024 | | :------------------------------------ | :--- | :--- | | Total revenue | $300,907 | $211,155 | | Gross profit | $184,817 | $129,223 | | Operating expenses | $120,807 | $104,294 | | Income from operations | $64,010 | $24,929 | | Net income | $60,589 | $24,391 | | Diluted Net income per share | $1.62 | $0.70 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) The balance sheets show an increase in total assets and stockholders' equity as of June 30, 2025 Condensed Consolidated Balance Sheets (as of June 30, 2025 vs. Dec 31, 2024) | Metric (in thousands) | June 30, 2025 | December 31, 2024 | | :-------------------- | :------------ | :---------------- | | Cash | $400,575 | $336,650 | | Total current assets | $558,129 | $497,216 | | Total assets | $890,522 | $804,076 | | Total current liabilities | $56,620 | $59,913 | | Total liabilities | $572,421 | $575,473 | | Total stockholders' equity | $318,101 | $228,603 | [Additional Information](index=2&type=section&id=Additional%20Information) [Webcast and Conference Call Details](index=2&type=section&id=Webcast%20and%20Conference%20Call%20Details) A conference call to discuss Q2 2025 financial results will be held on Thursday, July 30, 2025 - A conference call will be hosted on **Thursday, July 30, 2025, at 4:30 p.m. ET / 1:30 p.m. PT**[8](index=8&type=chunk) - A live and archived webcast of the event and the company's slide presentation will be available on the 'Investors' section of the TransMedics website[8](index=8&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This press release contains forward-looking statements regarding future results, strategy, and growth targets - Forward-looking statements address future results and events, including financial guidance, projected estimates, strategy, focus on achieving **10,000 US NOP transplants in 2028**, and investments for growth[10](index=10&type=chunk) - These statements are subject to risks and uncertainties, and actual results could differ materially due to factors such as financial result fluctuations, ability to attract and retain key personnel, indebtedness, profitability, funding needs, internal control weaknesses, dependence on OCS, regulatory approvals, and market acceptance[10](index=10&type=chunk)[11](index=11&type=chunk)[12](index=12&type=chunk) - The company undertakes no obligation to update any forward-looking statement, except as required by applicable law[12](index=12&type=chunk) [Investor Contact](index=4&type=section&id=Investor%20Contact) Contact information for investor relations is provided for any inquiries - Investor contact information: Brian Johnston, Laine Morgan, 332-895-3222, Investors@transmedics.com[13](index=13&type=chunk)

Core Insights - TransMedics Group, Inc. reported a strong financial performance for Q2 2025, with a 38% year-over-year revenue growth, reaching $157.4 million, driven by increased utilization of its Organ Care System (OCS) [2][3][11] - The company is focused on achieving a target of 10,000 US NOP transplants by 2028 and is increasing investments to support future growth [2][7] - Net income for Q2 2025 was $34.9 million, representing 22% of revenue, a significant increase from $12.2 million in Q2 2024 [6][11] Financial Performance - Total revenue for Q2 2025 was $157.4 million, a 38% increase from $114.3 million in Q2 2024, primarily due to higher OCS utilization in liver and heart transplants [3][11] - Gross margin remained stable at 61% for Q2 2025, consistent with the same period in 2024 [4][13] - Operating expenses increased to $60.0 million in Q2 2025 from $56.8 million in Q2 2024, mainly due to higher research and development investments [5][13] Financial Outlook - The company raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, indicating a 35% growth at the midpoint compared to the previous year [7][11] - Cash reserves as of June 30, 2025, were reported at $400.6 million, up from $336.7 million at the end of 2024 [6][14] Strategic Developments - TransMedics received conditional Investigational Device Exemption (IDE) approval from the FDA to initiate the Next-Gen OCS™ Lung trial [11] - The company launched the first-in-class OCS NOP digital ecosystem, NOP ACCESS™, across major NOP transplant programs in the U.S. [11]

Core Insights - TransMedics Group, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure [1][3] - The company will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:30 a.m. ET [1][2] Company Overview - TransMedics is recognized as the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation [3] - The company is headquartered in Andover, Massachusetts, and was founded to address the unmet need for more and better organs for transplantation [3] - TransMedics has developed technologies aimed at preserving organ quality, assessing organ viability prior to transplant, and potentially increasing the utilization of donor organs for treating end-stage heart, lung, and liver failure [3]

Core Insights - Wall Street analysts forecast TransMedics (TMDX) will report quarterly earnings of $0.48 per share, reflecting a year-over-year increase of 37.1% [1] - Anticipated revenues for the quarter are projected to be $147.37 million, representing a 28.9% increase compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - Analysts predict 'Net revenue by OCS product- OCS Lung net revenue' will reach $4.50 million, indicating a year-over-year decrease of 4.2% [4] - The estimate for 'Net revenue by OCS product- OCS Liver net revenue' is $108.56 million, showing a significant increase of 40.9% from the prior-year quarter [4] - 'Net revenue by OCS product- OCS Heart net revenue' is expected to be $32.38 million, reflecting a 3% increase from the previous year [4] Geographic Revenue Insights - 'Geographic Revenues- United States' is expected to be $142.05 million, indicating a year-over-year increase of 31% [5] - 'Geographic Revenues- All other countries' is projected to be $4.47 million, showing a decrease of 5.2% from the prior-year quarter [5] Stock Performance - TransMedics shares have decreased by 17.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of 4.9% [5] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [5]

Company Overview - TransMedics Inc. (NASDAQ: TMDX) is involved in the design, manufacturing, and selling of organ care systems (OCS) [1] - The stock price experienced a significant increase of 53% from April 23 to its interim high on June 11, followed by a decline of 25%, bringing the current price to $108 [1] Stock Performance - The stock rose to an interim high on June 11, indicating strong market interest and performance during that period [1] - The subsequent decline of 25% suggests volatility and potential market corrections following the peak [1]

Company Overview - TransMedics Group, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure [3] - The company is headquartered in Andover, Massachusetts, and is recognized as the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation [3] Financial Results Announcement - TransMedics will release its financial results for the second quarter of 2025 after market close on July 30, 2025 [1] - A conference call will be hosted by the management team at 4:30 p.m. ET / 1:30 p.m. PT on the same day [1] Investor Engagement - Investors can participate in the conference call by dialing (844) 676-6010 for domestic calls or (412) 634-6944 for international calls [2] - A live and archived webcast of the conference call will be available on the "Investors" section of the TransMedics website [2]

Core Insights - TransMedics (NASDAQ: TMDX) experienced a significant 55% drop in stock price following its Q3 2024 report, which met management's expectations [1] - The company has since recovered its stock price through strong execution and building trust with investors [1] Company Performance - The stock's decline was attributed to the Q3 2024 report, which did not exceed management's promises [1] - Recovery in stock price indicates effective management strategies and operational execution [1]

Group 1 - The article discusses the investment potential of TransMedics (TMDX) and highlights insights from expert analysts [1] - It emphasizes the importance of understanding market trends to identify potential investment opportunities [1] - The stock prices referenced are from May 28, 2025, indicating a specific timeframe for the analysis [1] Group 2 - The video published on July 3, 2025, serves as a resource for gaining valuable insights into the company's performance and market positioning [1] - The focus is on the exciting developments within TransMedics, suggesting a positive outlook for the company [1]

Group 1: TransMedics Group - TransMedics Group has seen its shares more than double this year due to positive company-specific developments despite initial challenges [1][3] - The company reported a 48% year-over-year revenue increase to $143.5 million in the first quarter, with net earnings per share doubling to $0.70 [4] - TransMedics raised its guidance for the full fiscal year 2025, indicating strong future prospects [4] - The company's organ care system (OCS) technology allows for longer storage of organs, improving usage rates compared to traditional methods [5][6] - There is significant growth potential in the organ donation market, with expectations of increased organ donations in the coming years [6][7] - The stock remains a buy for investors willing to hold long-term, even after its substantial increase in value this year [8] Group 2: FuboTV - FuboTV announced a merger with Disney's Hulu+ Live TV, enhancing its attractiveness by diversifying its offerings beyond sports streaming [9] - The merger led to the cancellation of the competing Venu initiative, which could have negatively impacted FuboTV's growth [10] - FuboTV received $220 million from former Venu backers and a $145 million term loan from Disney, providing a significant cash infusion [10] - With Disney as the majority shareholder, FuboTV benefits from the backing of a successful media giant, which is expected to support its growth in the streaming market [11] - Streaming accounted for 44.8% of television viewing time in the U.S. as of May, indicating a growing market with potential for further expansion [11] - Despite competition, FuboTV's new position post-merger and Disney's support suggest strong long-term upside potential, making the stock a buy [12]

Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].